Last update 24 Mar 2025

Crisugabalin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
克利加巴林, HSK 16149, HSK-16149
+ [2]
Target
Action
blockers
Mechanism
CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers)
Inactive Indication-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC12H19NO2
InChIKeyWCEFMBSFXJUREW-LIJGXYGRSA-N
CAS Registry2209104-84-5

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Neuralgia, Postherpetic
China
28 Jun 2024
Diabetic peripheral neuropathic pain
China
15 May 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeuralgiaPhase 3-30 May 2024
Peripheral neuralgiaPhase 3
China
17 Feb 2022
Pain, PostoperativePhase 2
China
08 Mar 2023
Post-herpetic neuritisPhase 1
China
20 Mar 2023
Renal InsufficiencyPhase 1
China
12 Dec 2022
Diabetic peripheral neuropathyPhase 1
China
01 Apr 2021
Diabetic NeuropathiesPhase 1
China
28 Dec 2018
FibromyalgiaIND Approval
China
17 Apr 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
134
Crisugabalin with Acetyl-Levo-Carnitine
fwqpnuygcq(aomptbmugs) = fwkslyfhuf ffpqzjbblm (ulaydzbmff )
Positive
21 Jun 2024
lipoic acid (LA) combined with acetyl-levo-carnitine
fwqpnuygcq(aomptbmugs) = ynavabsxxx ffpqzjbblm (ulaydzbmff )
Phase 2/3
301
Crisugabalin Besilate 40mg
vwojfipnun(aqitjswonf) = 86.4% subjects experienced a total of 1095 Treatment Emergent Adverse Events (TEAEs) during the study, including 203 drug-related TEAEs with the incidence of 38.9% nsjzpggeer (eehnblzcok )
Positive
14 Jun 2024
Not Applicable
-
Placebo
enrzdcqevq(muxqxhaewg) = ozzuknscyh ebuqkjjqvc (tlxjoeqwth )
Positive
20 Jun 2023
enrzdcqevq(muxqxhaewg) = rbiqhbtgau ebuqkjjqvc (tlxjoeqwth )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free